The team is studying whether inhibiting cellular processes in pancreatic tumors can stop the out-of-control growth that is characteristic of cancer. Pancreatic cancers with mutations in the KRAS gene are weakened when a protein called SHP2 is blocked in the RAS pathway—a cellular pathway that may be essential to the growth of pancreatic cancer cells. Another means to block this pathway involves a protein called MEK. In Round 1 pre-clinical work, the team has shown that inhibiting both of these components, they can better control growth of pancreatic cancertumors. In Round 2, the team will test the combination in a phase 1/1b clinical trial to better understand how this double inhibition works and to inform continued clinical trials.